Eli Lilly Touts Upbeat Weight-Loss Drug Results

Core Insights - The weight-loss drug market is becoming increasingly competitive, with Eli Lilly's Zepbound showing promising results against Novo Nordisk's Wegovy in a head-to-head trial, achieving an average weight loss of 20.2% compared to Wegovy's 13.7% [1] - Eli Lilly's stock has rebounded significantly, up 42.7% since the beginning of the year, and is currently experiencing a positive trend with gains in six out of the last seven sessions [2] - The options market for Eli Lilly shows a higher than usual interest in puts, with a 50-day put/call volume ratio of 0.92, indicating a notable shift in trading behavior [3] Company Performance - Eli Lilly's stock price increased by 2.2% to $830.80 following the positive news about Zepbound [1] - The stock has been recovering from early-November lows, indicating a strong performance trend [2] Options Market Activity - The Schaeffer's Volatility Index (SVI) for Eli Lilly is at 35%, which is in the low 25th percentile of its annual range, suggesting that options traders are currently expecting low volatility [4]